Daraxonrasib Pill Doubles Survival Pancreatic Cancer
SkimNews Take
Targeting specific genetic mutations like KRAS with an oral therapy offers a pathway to less invasive, more effective treatments for cancers previously considered untreatable, shifting the paradigm from broad chemotherapy to precision oncology.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- daraxonrasib was given daily to 500 metastatic pancreatic cancer patients who had progressed after chemotherapy, in a trial that compared it to continued standard chemotherapy infusions.
- daraxonrasib patients achieved a median overall survival of 13.2 months, nearly double the 6.7 months median survival of those receiving chemotherapy.
- daraxonrasib had a low discontinuation rate, with only 1% stopping due to side effects versus 11% in the chemotherapy arm.
- FDA has received a submission for daraxonrasib’s approval for use in metastatic pancreatic cancer after chemotherapy failure.
- ASCO presented the trial results on 31 May in Chicago, marking the first drug in decades to improve survival in advanced pancreatic cancer.
Why it matters: Metastatic pancreatic cancer patients gain a median 6.5‑month survival boost, while clinicians see fewer chemo‑related toxicities; the FDA review could unlock the first KRAS‑targeted oral therapy, reducing hospital visits and costs.
Ask SkimNews
